Shopping Cart
Remove All
Your shopping cart is currently empty
Emerfetamab (AMG 673) is a dual-specificity T-cell engager (bispecific T-cell engager) with an extended half-life that targets both CD33 and CD3. By redirecting T cells towards CD33+ cells, Emerfetamab induces T-cell mediated cytotoxicity against progenitor cells in acute myeloid leukemia (AML).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Emerfetamab (AMG 673) is a dual-specificity T-cell engager (bispecific T-cell engager) with an extended half-life that targets both CD33 and CD3. By redirecting T cells towards CD33+ cells, Emerfetamab induces T-cell mediated cytotoxicity against progenitor cells in acute myeloid leukemia (AML). |
| Synonyms | AMG-673 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | CD33/CD3 |
| Cas No. | 2250261-27-7 |
| Storage | -20°C for 1 year | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.